Bionano Genomics, Inc. 8-K

What Happened
Bionano Genomics, Inc. filed a Form 8-K on June 24, 2026 (Item 8.01), announcing it hired Alex Hastie, Ph.D. as the Company’s Chief Scientific Officer, with the appointment effective July 20, 2026. The company attached a June 24, 2026 press release as Exhibit 99.1 to the filing; the report was signed by Interim CEO Albert A. Luderer, Ph.D.

Key Details

• Appointment: Alex Hastie, Ph.D. named Chief Scientific Officer.
• Effective date: July 20, 2026.
• Filing date: Current Report on Form 8-K dated June 24, 2026 (Exhibit 99.1 = press release).
• Report signed by: Albert A. Luderer, Ph.D., Interim Chief Executive Officer.

Why It Matters
A CSO hire is a material leadership change relevant to Bionano’s scientific strategy, R&D direction, and technology development. The 8-K announces the appointment but does not disclose employment terms, compensation, or other financial impacts; investors should watch for follow-up disclosures or company communications that provide background, responsibilities, or any material financial arrangements related to this hire.